We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+9.81%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$79.2B
AUM Growth
+$3.07B
(+4%)
Cap. Flow
-$2.3B
Cap. Flow
% of AUM
-2.9%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
809
New
117
Increased
205
Reduced
335
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$331M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$327M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$319M |
| 4 |
Allison Transmission
ALSN
|
+$195M |
| 5 |
BA.PRA
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$853M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$294M |
| 3 |
NVIDIA
NVDA
|
+$266M |
| 4 |
Netflix
NFLX
|
+$190M |
| 5 |
Meta Platforms (Facebook)
META
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Consumer Discretionary | 18.83% |
| 3 | Communication Services | 18.1% |
| 4 | Healthcare | 11.79% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Progressive
PGR
$124B
| $987K | ﹤0.01% |
4,120
+295
| +8% | +$74.3K |
|
427
Arista Networks
ANET
$242B
| $979K | ﹤0.01% |
8,860
+3,308
| +60% | +$340K |
|
428
Cencora
COR
$62B
| $974K | ﹤0.01% |
+4,333
| New | +$1.02M |
|
429
AT&T
T
$165B
| $933K | ﹤0.01% |
40,992
-1,317
| -3% | -$29.6K |
|
430
iShares MSCI India Small-Cap ETF
SMIN
$772M
| $873K | ﹤0.01% |
11,417
+384
| +3% | +$31.4K |
|
431
Ingredion
INGR
$6.53B
| $859K | ﹤0.01% |
+6,244
| New | +$879K |
|
432
Citigroup
C
$227B
| $850K | ﹤0.01% |
12,069
+115
| +1% | +$7.75K |
|
433
Altria Group
MO
$109B
| $850K | ﹤0.01% |
16,253
-388
| -2% | -$20.7K |
|
434
Morningstar
MORN
$7.54B
| $836K | ﹤0.01% |
+2,483
| New | +$848K |
|
435
Hilton Worldwide
HLT
$70B
| $823K | ﹤0.01% |
3,328
-482
| -13% | -$118K |
|
436
RTX Corp
RTX
$302B
| $813K | ﹤0.01% |
7,022
+2,599
| +59% | +$314K |
|
437
SiriusXM
SIRI
$9.7B
| $792K | ﹤0.01% |
34,719
-404,029
| -92% | -$10.3M |
|
438
Carlisle Companies
CSL
$15.3B
| $777K | ﹤0.01% |
2,107
+27
| +1% | +$11.8K |
|
439
Automatic Data Processing
ADP
$109B
| $776K | ﹤0.01% |
2,650
-16
| -0.6% | -$4.73K |
|
440
Synchrony
SYF
$25.4B
| $759K | ﹤0.01% |
11,677
-222
| -2% | -$13.6K |
|
441
Vipshop
VIPS
$7.4B
| $753K | ﹤0.01% |
55,887
-14,509
| -21% | -$208K |
|
442
Agilent Technologies
A
$42B
| $751K | ﹤0.01% |
5,590
+5,288
| +1,751% | +$724K |
|
443
Cardinal Health
CAH
$55.5B
| $738K | ﹤0.01% |
6,240
-596
| -9% | -$69.6K |
|
444
AppFolio
APPF
$7.07B
| $724K | ﹤0.01% |
+2,936
| New | +$687K |
|
445
CF Industries
CF
$18.4B
| $722K | ﹤0.01% |
+8,463
| New | +$732K |
|
446
Valaris
VAL
$5.94B
| $705K | ﹤0.01% |
15,945
-155,630
| -91% | -$7.49M |
|
447
Edison International
EIX
$26.1B
| $673K | ﹤0.01% |
8,425
-349
| -4% | -$29.2K |
|
448
Fortinet
FTNT
$120B
| $669K | ﹤0.01% |
7,086
| – | – |
|
449
Applied Materials
AMAT
$415B
| $666K | ﹤0.01% |
4,094
-114
| -3% | -$20.7K |
|
450
Uber
UBER
$159B
| $654K | ﹤0.01% |
+10,842
| New | +$774K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q4 2024 Portfolio in Review
As of Q4 2024, Loomis, Sayles & Company held 809 positions worth $79.2B, up 4% from $76.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Loomis, Sayles & Company's Q4 2024 filing shows 117 new, 205 increased, 335 reduced and 91 closed positions. Its largest new stake was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M. The largest sale was Tesla, an estimated $853M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $331M increase.
- Loomis, Sayles & Company's biggest Q4 2024 reduction was Tesla, cutting an estimated $853M.
- Loomis, Sayles & Company fully exited Medpace in Q4 2024, selling an estimated $68.7M.
- Loomis, Sayles & Company's ten largest holdings make up 49% of its $79.2B portfolio in Q4 2024.
- Loomis, Sayles & Company opened 117 new positions and closed 91 in Q4 2024.
- Loomis, Sayles & Company's portfolio value rose 4% quarter-over-quarter to $79.2B.
Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.